Bariatric Surgery in Teens May Cut Diabetic Kidney Disease Risk
Decreased rates of hyperfiltration, elevated UAE seen among surgically treated obese teens with T2DM.
Diabetic Nephropathy
DIABETIC NEPHROPATHY
Patiromer Effective Up to 1 Year in Advanced Diabetic Kidney Disease
In a 52-week study, daily treatment with patiromer maintained normokalemia in patients, regardless of age.
SGLT2 Inhibitors Linked to Less Renal Deterioration Across All CKD Stages
Treatment with SGLT2 inhibitors empagliflozin and dapagliflozin may be associated with less decline in kidney function across different chronic kidney disease stages.
Tx Choice for T2DM in Obese Teens Tied to Later Kidney Disease Risk
Odds of diabetic kidney disease higher in obese teens receiving medical therapy versus bariatric surgery for T2DM
Spironolactone Does Not Prevent Diabetic Nephropathy in Type 2 Diabetes
In a study, spironolactone treatment was not significantly better than placebo in preventing diabetic nephropathy in patients with high-risk type 2 diabetes.
Canagliflozin Protects Against Renal Function Decline in Advanced Diabetic CKD
WASHINGTON—Canagliflozin showed a protective effect against kidney function decline in patients with type 2 diabetes and a baseline estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m2, new study findings presented at the American Society of Nephrology’s Kidney Week 2019 meeting suggest. The findings are from a post-hoc subgroup analysis of the phase 3 CREDENCE…
Aggressive Lowering of HbA1c in T1DM Does Not Reduce Eye, Kidney Disease
Sweden’s lower HbA1c target values not linked to further organ protection
FDA Approves Canagliflozin for Diabetic Kidney Disease
FDA’s approval of canagliflozin for slowing progression of diabetic nephropathy in patients with type 2 diabetes makes the drug the first new treatment option in nearly 20 years indicated for slowing diabetic kidney disease in these patients.
Metformin Superior for Lowering CV Risk in Diabetics Who Progress to CKD
Continued monotherapy with metformin, compared with a sulfonylurea, is associated with a lower risk for major adverse cardiovascular events (MACE) among patients with type 2 diabetes who experienced reduced kidney function.
Review: SGLT2 Inhibitors Provide Clear Renal Benefits in Type 2 Diabetes
New review identifies benefits of sodium-glucose co-transporter-2 (SGLT2) inhibitors at almost all levels of kidney function.
Want to read more?
Please login or register first to view this content.
Next post in Diabetic Nephropathy
